Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satofumi Iida

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Drug Metabolism and Pharmacokinetics|July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2aTomohisa Saito, Satofumi Iida, Takehiko Kawanishi
The Journal of Pharmacy and Pharmacology|December 16, 2010
Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulationSatofumi Iida, Takehiko Kawanishi, Masahiro Hayashi
Journal of Clinical Pharmacology|July 14, 2017
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and SimulationTomohisa Saito, Satofumi Iida, Kimio Terao, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 4, 2009
The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adultsSatofumi Iida, Haruki Kinoshita, Takehiko Kawanishi, et al.
British Journal of Clinical Pharmacology|September 11, 2008
Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failureSatofumi Iida, Haruki Kinoshita, Nicholas H G Holford
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2015
Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietinKiyohiko Nakai, Kumiko Miyata, Satofumi Iida, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 6, 2014
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic propertiesKiyohiko Nakai, Masato Tobinai, Junko Hashimoto, et al.
Clinical Pharmacokinetics|November 19, 2014
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatmentKiyohiko Nakai, Satofumi Iida, Masato Tobinai, et al.
Drug Metabolism and Pharmacokinetics|January 15, 2014
Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patientsKiyohiko Nakai, Russell Wada, Satofumi Iida, et al.
The Journal of Pharmacy and Pharmacology|July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitorTomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Pharmacokinetics|July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2aTomohisa Saito, Satofumi Iida, Takehiko Kawanishi
The Journal of Pharmacy and Pharmacology|December 16, 2010
Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulationSatofumi Iida, Takehiko Kawanishi, Masahiro Hayashi
Journal of Clinical Pharmacology|July 14, 2017
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and SimulationTomohisa Saito, Satofumi Iida, Kimio Terao, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 4, 2009
The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adultsSatofumi Iida, Haruki Kinoshita, Takehiko Kawanishi, et al.
British Journal of Clinical Pharmacology|September 11, 2008
Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failureSatofumi Iida, Haruki Kinoshita, Nicholas H G Holford
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2015
Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietinKiyohiko Nakai, Kumiko Miyata, Satofumi Iida, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 6, 2014
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic propertiesKiyohiko Nakai, Masato Tobinai, Junko Hashimoto, et al.
Clinical Pharmacokinetics|November 19, 2014
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatmentKiyohiko Nakai, Satofumi Iida, Masato Tobinai, et al.
Drug Metabolism and Pharmacokinetics|January 15, 2014
Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patientsKiyohiko Nakai, Russell Wada, Satofumi Iida, et al.
The Journal of Pharmacy and Pharmacology|July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitorTomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Pageof 2